Medicine screening technologies can help rapidly detect substandard and falsified medicines in the field. A risk-based testing approach that utilizes screening technologies to identify products for full laboratory testing has become the best practice, but rapid developments in technologies have left regulators with limited information on their capabilities. The Technology Review program rigorously evaluates available and emerging screening technologies and publishes these evaluations to inform the global health community of their relative strengths and limitations.
USP invested in its Technology Review program after discovering that regulators, inspectors, and quality control laboratories around the world need more information to make decisions about screening technologies based on experience with implementing the Promoting the Quality of Medicines program, which is funded by the U.S. Agency for International Development.
With a 13-member volunteer Expert Panel that provides technical guidance and oversight, USP's Technology Review program:
- Develops standards and guidelines for evaluating medicine quality screening technologies
- Generates and disseminates tailored information on the capabilities of these technologies through a two-step review process: a lab-based technical performance evaluation and a collaborative field-based utility evaluation
- Builds the knowledge of key stakeholders to appropriately procure and sustainably utilize screening technologies for the purposes of combating substandard and falsified medicines
- Stimulates targeted investment in the development and enhancement of new screening technologies
USP Technology Reviews:
- Paper Analytical Device
- Target-ID review
- Speedy Breedy review
- CBEx Handheld Raman Spectrometer
- ASD QualitySpec® (Trek)
- Global Pharma Health Fund( GPHF)-Minilab™
Screening Technology Overviews: